Capecitabine as Adjuvant Therapy for Biliary Tract Cancer: BILCAP Trial
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On March 22, 2022, John Bridgewater and colleagues from the UCL Cancer Institute published the long-term follow-up results of the BILCAP Phase 3 clinical trial in the Journal of Clinical Oncology. The study investigated the efficacy of capecitabine as an adjuvant therapy for patients with biliary tract cancer (BTC) who had undergone radical surgical resection.
Study Design: BILCAP Phase 3 Trial
BILCAP was a multicenter, randomized Phase 3 trial involving 447 patients who had undergone complete resection for BTC. Participants were randomized 1:1 into two groups:
- Capecitabine Group (N=223): Capecitabine 1,250 mg/m² twice daily on days 1–14 of a 21-day cycle, for a total of 8 cycles.
- Observation Group (N=224): Monitoring without active adjuvant therapy.
The primary endpoint was overall survival (OS).
Long-term Follow-up Results (Median 106 Months)
- Median Overall Survival: 49.6 months for the capecitabine group vs. 36.1 months for the observation group.
- Risk Reduction: The capecitabine group showed a 16% reduction in the risk of death (Hazard Ratio [HR] = 0.84).
- Adjusted Analysis: After adjusting for factors such as nodal status, tumor grade, and sex, the risk of death was reduced by 26% (HR = 0.74).
Conclusion
The authors concluded that adjuvant capecitabine significantly improves overall survival in patients with BTC following surgical resection. Based on these findings, capecitabine is established as a standard of care for adjuvant therapy in this patient population.
Source: Journal of Clinical Oncology - BILCAP Trial Results
#BiliaryTractCancer #Cholangiocarcinoma #Capecitabine #BILCAPTrial #CancerResearch #AdjuvantTherapy
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4